Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.11.2023 | Case report

Crizotinib/docetaxel/gemcitabine

Lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Aminimoghaddam S, et al. Epithelioid Inflammatory Myofibroblastic Sarcoma With Poor Response to Crizotinib: A Case Report. Clinical Medicine Insights: Case Reports 16: 1-6, Jan 2023. Available from: URL: https://dx.doi.org/10.1177/11795476231163954 Aminimoghaddam S, et al. Epithelioid Inflammatory Myofibroblastic Sarcoma With Poor Response to Crizotinib: A Case Report. Clinical Medicine Insights: Case Reports 16: 1-6, Jan 2023. Available from: URL: https://​dx.​doi.​org/​10.​1177/​1179547623116395​4
Metadaten
Titel
Crizotinib/docetaxel/gemcitabine
Lack of efficacy
Publikationsdatum
01.11.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-49505-y

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Imiquimod

Case report

Elasomeran